This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Jan 2012

Epizyme Achieves Eisai Milestone

In total, Epizyme is eligible for more than $200 million in R&D and sales milestones, as well as double-digit royalties.

Epizyme, Inc., a biopharmaceutical company located in Cambridge, MA, has achieved a preclinical milestone in its alliance with Eisai Co., Ltd., triggering a $4 million milestone payment.

 

The companies established a worldwide strategic alliance in March 2011 to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.

 

In total, Epizyme is eligible for more than $200 million in R&D and sales milestones, as well as double-digit royalties. Additionally, Eisai will fund 100% of R&D through human proof-of-concept, at which point Epizyme has the right to opt into a profit share and co-commercialization arrangement for the U.S.

 <

Related News